At the core of every AI coding agent is a technology called a large language model (LLM), which is a type of neural network ...
Lunit’s new collaboration with Daiichi Sankyo integrates AI-driven digital pathology tools into oncology translational ...
News-Medical.Net on MSN
Laughing gas shows fast antidepressant effects in early clinical trials
A systematic review and meta-analysis in eBioMedicine shows that nitrous oxide can rapidly reduce depressive symptoms within hours, particularly at higher doses, but effects are short-lived after ...
5don MSN
Google Introduces Gemini 3 Flash A Faster More Efficient AI Model for Everyday and Enterprise Use
Google has unveiled Gemini 3 Flash, a groundbreaking AI model engineered for speed, cost-effectiveness and intelligent ...
Software engineering does not disappear. But the path in changes: junior roles require stronger fundamentals, better ...
News-Medical.Net on MSN
Shingles vaccination is linked to fewer dementia diagnoses and deaths in older adults
A large quasi-experimental study in Wales shows that eligibility for shingles vaccination is linked to fewer new mild cognitive impairment diagnoses and lower dementia-related mortality. Benefits ...
An ocean-mining company has funded some of the most comprehensive scientific studies of the deep seabed to date, and peer-reviewed results have begun to emerge. A collage of foraminifera, a kind of ...
Urban raccoons are developing shorter snouts, revealing how city life is subtly reshaping wildlife anatomy and behavior.
In the realm of big data, executives are frequently presented with a false dichotomy: high performance or low cost. The prevailing assumption, lingering from the days of on-premise hardware, is that ...
Background Predicting progression to aortic valve replacement (AVR) in moderate aortic stenosis (AS) is challenging. This ...
Vancouver, BC, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Skyharbour Resources Ltd . (TSX-V: SYH) (OTCQX: SYHBF) (Frankfurt: SC1P) (“Skyharbour” or the “Company”) is ...
Arcturus Therapeutics' stock slides 59%, primarily due to mixed interim results from the phase II study of its investigational inhaled cystic fibrosis therapy, ARCT-032.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results